Adaptive Biotechnologies second-quarter financial resultsDespite the adjusted earnings beat, Adaptive Biotechnologies remains unprofitable, with a reported negative net margin and negative return on equity. Adaptive Biotechnologies insider sale reportHedge Funds Weigh In On Adaptive BiotechnologiesA number of hedge funds have recently modified their holdings of the business. Adaptive Biotechnologies Stock PerformanceThe stock’s 50-day moving average is $19.05 and its two-hundred day moving average is $16.56. Adaptive Biotechnologies Company Profile(Get Free Report)Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Recommended StoriesReceive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.